Brent Rexer
Faculty Member
Last active: 2/13/2015

Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response.

Rexer BN, Arteaga CL
Breast Cancer Res. 2014 16 (2): 303

PMID: 25032256 · PMCID: PMC4053204 · DOI:10.1186/bcr3635

A recent study by Niepel and colleagues describes a novel approach to predicting response to targeted anti-cancer therapies. The authors used biochemical profiling of signaling activity in basal and ligand-stimulated states for a panel of receptor and intracellular kinases to develop predictive models of drug sensitivity. In some cases, the response to ligand stimulation predicted drug response better than did target abundance or genomic alterations in the targeted pathway. Furthermore, combining biochemical profiles with genomic information was better at predicting drug response. This work suggests that incorporating biochemical signaling profiles with genomic alterations should provide powerful predictors of response to molecularly targeted therapies.

MeSH Terms (11)

Antineoplastic Agents Biomarkers, Tumor Breast Neoplasms Female Gene Expression Regulation, Neoplastic Humans Outcome Assessment, Health Care Phosphatidylinositol 3-Kinases Proto-Oncogene Proteins c-akt Signal Transduction Transcriptome

Connections (1)

This publication is referenced by other Labnodes entities:

Links